Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Oncology
Acute Myeloid Leukemia In Children In Pakistan: An Audit, S. Zaki, I. A. Burney, Mohammad Khurshid
Acute Myeloid Leukemia In Children In Pakistan: An Audit, S. Zaki, I. A. Burney, Mohammad Khurshid
Section of Haematology/Oncology
Objective: To see the clinical features and treatment of children with Acute Myeloid Leukemia (AML) in Pakistan. Setting: Tertiary referral at a specialist Hematology/Oncology center.
Methods: Retrospective, chart-based review of children (less than 14 years) admitted to the hospital with a diagnosis of AML between January 1987 and August 1997.
Results: A total of 23 patients were admitted. There were 18 males and 5 females. The mean age was 8 5 years. M3 was the commonest morphological subtype (43%). Twenty- two percent of the patients presented with hyperleucocytosis (TLC> 100 x i09 /L) and 95% with an elevated …
Lack Of Benefit Of Granulocyte Macrophage Or Granulocyte Colony Stimulating Factor In Patients With Febrile Neutropenia, T. Siddiqui, I. A. Burney, A. Salam, G. N. Kakepoto, Mohammad Khurshid, R. A. Smego
Lack Of Benefit Of Granulocyte Macrophage Or Granulocyte Colony Stimulating Factor In Patients With Febrile Neutropenia, T. Siddiqui, I. A. Burney, A. Salam, G. N. Kakepoto, Mohammad Khurshid, R. A. Smego
Section of Haematology/Oncology
Objectives: To compare the clinical benefits of granulocyte-colony stimulating factor (G-CSF) or granulocyte macrophage-colony stimulating factor (GM-CSF) plus standard supportive care to supportive care alone among cancer patients with febrile neutropenia.
Methods: Clinical data were collected retrospectively from 148 consecutive cancer patients with neutropenia and fever. Patients had hematologic (i.e., acute leukemias or lymphoproliferative disorders) or non-hematologic malignancies (i.e., solid tumors including carcinoma of breast, lung, or colon). Clinical variables analyzed included: age and sex; underlying malignancies; chemotherapy regimens; symptoms at time of presentation; duration of fever prior to study enrollment; days from chemotherapy until administration of GM-CSF or …